CL2012001636A1 - Supositorio rectal de mesalamina , en donde las particulas de mesalamina tienen un area de superficie de 0,1 m2/g a 1,3 m2/g, util en el tratamiento de proctitis ulcerosa activa. - Google Patents

Supositorio rectal de mesalamina , en donde las particulas de mesalamina tienen un area de superficie de 0,1 m2/g a 1,3 m2/g, util en el tratamiento de proctitis ulcerosa activa.

Info

Publication number
CL2012001636A1
CL2012001636A1 CL2012001636A CL2012001636A CL2012001636A1 CL 2012001636 A1 CL2012001636 A1 CL 2012001636A1 CL 2012001636 A CL2012001636 A CL 2012001636A CL 2012001636 A CL2012001636 A CL 2012001636A CL 2012001636 A1 CL2012001636 A1 CL 2012001636A1
Authority
CL
Chile
Prior art keywords
mesalamine
useful
treatment
surface area
particles
Prior art date
Application number
CL2012001636A
Other languages
English (en)
Spanish (es)
Inventor
David Powel
Yves Gauthier Carl Dumoulin
Hugues Moreau
Original Assignee
Aptalis Pharma Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43901620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001636(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aptalis Pharma Canada Inc filed Critical Aptalis Pharma Canada Inc
Publication of CL2012001636A1 publication Critical patent/CL2012001636A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2012001636A 2009-12-16 2012-06-15 Supositorio rectal de mesalamina , en donde las particulas de mesalamina tienen un area de superficie de 0,1 m2/g a 1,3 m2/g, util en el tratamiento de proctitis ulcerosa activa. CL2012001636A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/639,645 US8436051B2 (en) 2007-06-08 2009-12-16 Mesalamine suppository

Publications (1)

Publication Number Publication Date
CL2012001636A1 true CL2012001636A1 (es) 2012-10-12

Family

ID=43901620

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001636A CL2012001636A1 (es) 2009-12-16 2012-06-15 Supositorio rectal de mesalamina , en donde las particulas de mesalamina tienen un area de superficie de 0,1 m2/g a 1,3 m2/g, util en el tratamiento de proctitis ulcerosa activa.

Country Status (14)

Country Link
US (2) US8436051B2 (enExample)
EP (1) EP2512443A2 (enExample)
JP (1) JP2013514979A (enExample)
KR (1) KR20120104604A (enExample)
CN (1) CN102970971A (enExample)
AU (1) AU2010339837A1 (enExample)
CA (2) CA2690450A1 (enExample)
CL (1) CL2012001636A1 (enExample)
IL (1) IL220397A0 (enExample)
MX (1) MX2012006902A (enExample)
RU (1) RU2012125186A (enExample)
SG (1) SG181169A1 (enExample)
WO (1) WO2011084638A2 (enExample)
ZA (1) ZA201204422B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
ES2377225T3 (es) 2008-09-19 2012-03-23 OERLIKON TRADING AG, TRÜBBACH Método para producir capas de óxido metálico mediante vaporización por arco
CN103153944A (zh) * 2010-09-10 2013-06-12 法莫再尔公司 晶态5-氨基水杨酸的制备方法
WO2013059768A1 (en) * 2011-10-20 2013-04-25 Aptalis Pharma U.S., Inc. Therapeutic agents for treating gastrointestinal disorders associated with inflammation of the gastrointestinal tract
CN103622974B (zh) * 2013-12-05 2016-04-20 武汉武药科技有限公司 一种含美沙拉嗪和n-乙酰半胱氨酸的复方栓剂及其制备方法
US20160175271A1 (en) * 2014-12-19 2016-06-23 Gavis Pharmaceuticals Rectal suppository for ulcerative colitis
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
AR120360A1 (es) * 2019-10-31 2022-02-09 Scherer Technologies Llc R P Cápsula de supositorio
KR20250042058A (ko) 2023-09-19 2025-03-26 한양대학교 산학협력단 염증성 장 질환 치료용 약학적 조성물

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689514A (en) 1969-05-21 1972-09-05 Schlueter Edelfett Suppository vehicle and process of making same
US4211777A (en) 1977-11-25 1980-07-08 Fisons Limited Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
US4298595A (en) 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4374932A (en) 1981-06-08 1983-02-22 G. D. Searle & Co. 5-ASA Drug delivery system
DE3151196A1 (de) 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
JPH0816051B2 (ja) 1988-12-07 1996-02-21 エスエス製薬株式会社 徐放性坐剤
US5629012A (en) 1991-06-17 1997-05-13 Farmaceutisk Laboratorium Ferring A/S Process for producing suppositories by compression and suppositories obtained by the process
GB9201857D0 (en) 1992-01-29 1992-03-18 Smithkline Beecham Plc Novel compound
US5389375A (en) 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
WO1997009035A1 (en) 1995-09-07 1997-03-13 Taisho Pharmaceutical Co., Ltd. Long-lasting composition for rectal administration
JPH09323934A (ja) 1996-05-31 1997-12-16 Kanebo Ltd 保存安定性の改善された坐剤
WO1998043667A1 (en) 1997-04-01 1998-10-08 Borody Thomas J Methods and compositions for treating inflammatory bowel disease
ES2224428T3 (es) 1997-09-26 2005-03-01 Celltech Pharma Europe Limited Composicion farmnaceutica para el tratamiento de la enfermedad inflmatoria intestinal.
WO1999017737A1 (fr) 1997-10-08 1999-04-15 Taisho Pharmaceutical Co., Ltd. Composition de suppositoire
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US6610674B1 (en) 1999-09-28 2003-08-26 University Of Pennsylvania Method of treating inflammatory conditions with progesterone analogs
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20020037855A1 (en) 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
CA2420576C (en) 2000-08-29 2005-06-14 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
US20060104946A1 (en) 2002-08-23 2006-05-18 Zymogenetics, Inc. Method for treating inflammatory bowel disease
US7312243B1 (en) 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
EP1722630A4 (en) 2004-01-20 2009-05-27 Richard F Harty COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP1751096A4 (en) 2004-05-27 2009-01-07 Antibe Therapeutics Inc 4- OR 5- AMINOSALICYLIC ACID SALT
CZ2004945A3 (cs) 2004-09-08 2006-01-11 Pliva - Lachema A. S. Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
US20080020018A1 (en) 2004-09-27 2008-01-24 Joey Moodley Combination Products
US7250445B1 (en) 2005-01-14 2007-07-31 Ehrenpreis Eli D Anti-oxidant suppository for treating radiation proctopathy and other anorectal disorders
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
AU2007223988A1 (en) 2006-03-07 2007-09-13 Zalicus Inc. Compositions and methods for the treatment of immunoinflammatory disorders
US20070240236A1 (en) 2006-04-05 2007-10-11 Oklahoma Medical Research Foundation O-glycans in the treatment of inflammatory bowel disease and cancers
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
JP2009535419A (ja) 2006-05-01 2009-10-01 ナポ ファーマシューティカルズ インク． 便秘型過敏性腸症候群の治療方法
US7842709B2 (en) 2006-09-08 2010-11-30 Ore Pharmaceuticals Inc. Method for treating inflammatory diseases of the digestive tract
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) * 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository

Also Published As

Publication number Publication date
CA2690450A1 (en) 2011-06-16
WO2011084638A3 (en) 2012-04-05
US20130231310A1 (en) 2013-09-05
SG181169A1 (en) 2012-07-30
RU2012125186A (ru) 2014-01-27
US20100105639A1 (en) 2010-04-29
US8436051B2 (en) 2013-05-07
EP2512443A2 (en) 2012-10-24
JP2013514979A (ja) 2013-05-02
MX2012006902A (es) 2012-10-05
CN102970971A (zh) 2013-03-13
AU2010339837A1 (en) 2012-06-28
US9884018B2 (en) 2018-02-06
WO2011084638A2 (en) 2011-07-14
IL220397A0 (en) 2012-08-30
CA2784772A1 (en) 2011-07-14
KR20120104604A (ko) 2012-09-21
ZA201204422B (en) 2013-08-28

Similar Documents

Publication Publication Date Title
CL2012001636A1 (es) Supositorio rectal de mesalamina , en donde las particulas de mesalamina tienen un area de superficie de 0,1 m2/g a 1,3 m2/g, util en el tratamiento de proctitis ulcerosa activa.
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
CL2012003470A1 (es) Una composicion solida que comprende 1) un compuesto inhibidor del hcv de formula definida, o una sal farmaceuticamente aceptable de este, en una forma amorfa, 2) un polimero hidrofilico, y opcionalmente 3) un agente tensoactivo; su proceso de preparacion, util para tratar una infeccion del hcv.
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
BR112015029686A2 (pt) composições para o tratamento de superfícies compreendendo corantes fotocrômicos
UY34474A (es) Composiciones, forma de dosificación y métodos para tratar el virus de la hepatitis C.
CR20110560A (es) Métodos de tratamiento para tumores sólidos
MX355294B (es) Artículos para el cuidado personal que tienen composiciones para el cuidado personal que tienen múltiples zonas amoldables.
BR112015020466A2 (pt) inibidores de cdc7
MX386489B (es) Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
BR112014007649A2 (pt) material estruturante, e, método para o tratamento de uma formação subterrânea
UY34387A (es) Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización.
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
EP2706597A4 (en) SURFACE TREATMENT METHOD FOR ANODE-ACTIVE MATERIAL PARTICLES AND ANODE-ACTIVE MATERIAL PARTICLES MOLDED IN THIS PROCEDURE
AR093986A1 (es) Cuerpos de carbono ferromagneticos y proceso de produccion
MX357510B (es) Metodos para tratar ataques de gota.
EA201491286A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
MX2013011932A (es) Inhibidores de parp para el tratamiento de cipn.
CR20110403A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia
CL2009000690A1 (es) Material filtrante para usar en articulo para fumar, que comprende carbono que se ha sometido a una alteracion de superficie mediante procesamiento en plasma; articulo para fumar; y metodo para fabricar un material filtrante.
HUE049383T2 (hu) Eljárás ipari víz kezelésére
FI20115258L (fi) Menetelmä tuhkan käsittelemiseksi ja tuhkan käsittelylaitos
BR112013019822A2 (pt) método para remover água a partir de um material que possui água livre associada, produto, método para produzir estruvita substancialmente seca, e, composição para secagem química
JP2013067908A5 (enExample)